STAT

The list price is not right: Trump’s plan to force pharma to advertise prices is misguided

The proposed rule to list drug prices in ads is likely to create confusion — and it lacks teeth.

Talk about a non-starter.

For months, the White House has promised action on rising drug prices, yet, so far, little has happened. Now, though, the administration is trumpeting a rule to force drug makers to disclose prices in TV ads.

The hope is that companies will be persuaded to compete on price if “relevant information” is provided for any drug that is available under Medicare or Medicaid, if the price is more than $35 a month.

The notion may be well-intended,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

Related Books & Audiobooks